Bone and Joint Infection Clinical Trial
Official title:
Evaluation of the Tolerance of Anti-MRSA Betalactamines (Ceftaroline / Ceftobiprole) in the Management of BJI / PJI: a Retrospective Study in a Reference Center
Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority
of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the
use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in
empirical therapy, while awaiting the microbiological results. Vancomycin is not considered
as a safe antibiotic, and daptomycin is frequently an alternative option.
Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant
staphylococci. As some data report a synergistic activity with daptomycin, they could be an
option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Completed |
NCT03627000 -
Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection
|
||
| Completed |
NCT03311113 -
Adherence to Oral Antibiotics In Patients With Osteoarticular Infections
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Completed |
NCT03209921 -
Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
|
N/A | |
| Completed |
NCT04418882 -
Septic Management and Outcome of Open Fracture
|
||
| Completed |
NCT05248490 -
Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home
|
N/A | |
| Completed |
NCT03624855 -
Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
|
||
| Recruiting |
NCT04496024 -
Ofloxacin Concentration-toxicity Relationship in the Elderly
|
N/A | |
| Recruiting |
NCT04933344 -
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
|
||
| Recruiting |
NCT04538053 -
BonE and Joint Infections - Simplifying Treatment in Children Trial
|
Phase 4 | |
| Completed |
NCT04373278 -
Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
|
||
| Completed |
NCT03209934 -
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center
|
N/A | |
| Recruiting |
NCT02817711 -
Lyon BJI Cohort Study
|
N/A | |
| Recruiting |
NCT03611634 -
Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
|
||
| Completed |
NCT03177369 -
Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
|
N/A | |
| Recruiting |
NCT04722926 -
Lyon PJI Retrospective Cohort Study
|
||
| Completed |
NCT03852784 -
Osteoarticular Infections With Pneumococcal
|
||
| Recruiting |
NCT03796104 -
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
|